Zacks_Analysts' Blog : BSD MicroThermX Featured at CIRSE - Analyst Blog

Cancer treatment systems maker BSD Medical Corp. (BSDM) reported that its MicroThermX Microwave Ablation System (“MicroThermX”) was showcased at the international meet of the Cardiovascular and Interventional Radiological Society of Europe (“CIRSE”).

The innovative therapy system was featured at the Utah-based company’s exhibition booth at the CIRSE meet, held in Munich, Germany, on September 10-14. CIRSE is the largest meeting in the world dedicated to interventional radiology/oncology products with more than 5,000 physicians across 70 nations having attended the event.

The CIRSE meet focused on the rapidly growing field of interventional oncology. Several presentations made at the meeting projected the benefits of thermal ablation techniques in treating solid tumors.

BSD Medical used the CIRSE meeting to bolster the profile of its MicroThermX system and strengthen its association with international interventional oncologists and key opinion leaders. A large number of interventional oncologists requested the demonstration of the ground-breaking device at the meet. Moreover, the company’s senior sales and marketing managers held strategic meetings with leading international distributors.   

The MicroThermX system hit the U.S. and European markets in December 2010 and January 2011, respectively. MicroThermX leverages BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.

The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. As such, it can be used by both surgeons and interventional radiologists.

BSD Medical competes with established players like Boston Scientific (BSX) and Angiodynamics (ANGO) in the thermal ablation market. The global market for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.